Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Long-Term Debt, Maturity, after Year Five

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Long-Term Debt, Maturity, after Year Five

AKEBIA THERAPEUTICS, INC. (AKBA) had Long-Term Debt, Maturity, after Year Five of $0 as of 2021-12-31, per its 10-K filed 2022-03-01.

Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2022-03-01

  • 2021-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
  • 2020-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
Period endLong-Term Debt, Maturity, after Year Five
2021-12-31$0.00
10-K · filed 2022-03-01
2020-12-31$0.00
10-K · filed 2021-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33